Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven dx of recurrent or metastatic breast cancer~* Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer. Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease. Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease.~* Unidimensionally measurable dz (by RECIST)~* At least 18 yrs of age~* SWOG PS 0-2~* AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0~* Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln~* Creatinine less than or equal to 2.0~* Fully recovered from acute toxicities secondary to prior tx~* Signed informed consent (including HIPAA authorization)~* Peripheral neuropathy grade 0-1~Exclusion Criteria~* Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \>12 mos prior to enrollment.~* Underlying medical, psychiatric, or social conditions that would preclude patient from receiving tx~* Peripheral neuropathy greater than or equal to Gr 2~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).